Allogeneic stem cell transplant with ⍺/β CD3+ T-cell and CD19+ B-cell depleted graft for Acute Lymphoblastic Leukemia

"Participants as young as 6 months old and up to the age of 39 are eligible for enrollment based on the inclusion criteria outlined for this research study."

"This research trial is open for enrollment to 20 individuals aged between 6 months and 39 years who are presently diagnosed with acute lymphoblastic leukemia. Eligible participants must satisfy the subsequent conditions: ii. AML, i. ALL, AML displaying persistent minimal residual disease (MRD) in CR1(≥0.01% on flow or continuing abnormal karyotype observed via cytogenetics), AML CR2 onwards, AML facing refractory relapse but having ≤15% bone marrow leukemia blasts, High-risk ALL encompassing any of the following characteristics: (t(9;22) or presence of"

"Our team at Power rates the safety of Allogeneic stem cell transplant with ⍺/β CD3+ T-cell and CD19+ B-cell depleted graft as 2 on a scale from 1 to 3. This evaluation is based on the current Phase 2 trial status, where some evidence exists supporting safety but not efficacy."

"As per details on clinicaltrials.gov, recruitment for this trial is not ongoing. The study was initially listed on April 1st, 2024 and last revised on February 19th, 2024. Although this particular trial is closed for enrollment, there are currently 3099 other studies actively seeking participants."